Page 1 of 77
NSG1 550 PHARMACOLOGY EXAM 2 LATEST VERSION
QUESTIONS AND ANSWERS 2026 EDITION
NSG1 550 PHARMACOLOGY EXAM 2: PRACTICE QUESTIONS WITH RATIONALES
QUESTIONS 1-20: PHARMACOKINETICS AND PHARMACODYNAMICS
1. A patient with renal impairment is receiving a medication that is primarily
eliminated by the kidneys. Which pharmacokinetic parameter would be most
affected, requiring dosage adjustment?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Protein binding
Correct Answer: C
Rationale: For drugs eliminated primarily by the kidneys, renal impairment reduces the
clearance rate, which increases the drug's half-life and prolongs its duration of action.
Volume of distribution (A) is affected by factors such as body composition and tissue
binding rather than renal function. Bioavailability (B) relates to the fraction of an
administered dose that reaches systemic circulation. Protein binding (D) can be altered
by conditions affecting albumin levels, not directly by renal function. In clinical practice,
dosage adjustment (e.g., lower dose, longer interval) is required to prevent drug
accumulation and toxicity when renal clearance is reduced .
2. A drug with high first-pass metabolism is administered. Which route of
administration would best bypass first-pass metabolism?
A. Oral administration
B. Intravenous administration
, Page 2 of 77
C. Sublingual administration
D. Intramuscular administration
Correct Answer: C
Rationale: Sublingual administration allows the drug to be absorbed through the oral
mucosa directly into the systemic circulation, completely bypassing the hepatic portal
system and first-pass metabolism. Intravenous (B) administration also bypasses first-
pass metabolism but requires specialized training for administration. Oral (A)
administration subjects the drug to hepatic first-pass metabolism because it is
absorbed from the GI tract into the portal circulation. Intramuscular (D) administration
avoids first-pass metabolism but involves slower absorption than sublingual .
3. The therapeutic index of a drug is best defined as:
A. The ratio of the median effective dose to the median lethal dose
B. The dose required to produce a therapeutic effect
C. The potency of the drug compared to another drug
D. The maximum effect a drug can produce
Correct Answer: A
Rationale: The therapeutic index (TI) is a safety parameter calculated as the ratio of the
median lethal dose (LD50, dose that kills 50% of subjects) to the median effective dose
(ED50, dose that produces a therapeutic effect in 50% of subjects). A larger therapeutic
index indicates a wider margin of safety, whereas a narrow therapeutic index (e.g.,
warfarin, lithium, phenytoin, digoxin) requires careful monitoring . Potency (C) is defined
by the dose required to achieve a given effect, while efficacy (D) refers to the maximum
effect a drug can produce .
4. A patient is prescribed a drug that is 95% protein-bound and has a narrow
therapeutic index. The nurse should monitor this patient closely for which potential
risk?
A. Enhanced drug effect due to decreased protein binding
B. Reduced drug effect due to increased protein binding
C. Increased drug excretion due to protein saturation
D. No change in drug effect because the drug is highly protein-bound
Correct Answer: A
Rationale: For drugs that are highly protein-bound (e.g., 95%), only the unbound (free)
fraction is pharmacologically active. If a second drug with higher protein-binding affinity
, Page 3 of 77
is co-administered or if protein binding is decreased, the free fraction of the original
drug increases. This can lead to increased drug effect and toxicity even if the total
serum concentration remains within the therapeutic range. This is a critical
consideration for drugs with a narrow therapeutic index, such as phenytoin, warfarin,
and digoxin. The nurse should monitor for signs of toxicity in such situations .
5. A drug that acts as a full agonist at a receptor will produce:
A. No effect regardless of receptor occupancy
B. A maximal effect at 100% receptor occupancy
C. A maximal effect at less than 100% receptor occupancy
D. An effect that is less than that of a partial agonist
Correct Answer: C
Rationale: A full agonist is capable of producing a maximal tissue response. In many
receptor systems, it is not necessary for the agonist to occupy 100% of the receptors to
produce a maximal effect because of the phenomenon of receptor spareness. The
presence of spare receptors means that a maximal response can be achieved when
only a fraction of the receptors are occupied. Partial agonists (D) produce a submaximal
effect even at 100% receptor occupancy .
QUESTIONS 21-40: AUTONOMIC PHARMACOLOGY
21. A patient receiving atropine for bradycardia should be monitored for which of
the following adverse effects?
A. Miosis
B. Increased salivation
C. Tachycardia
D. Urinary retention
Correct Answer: C and D
Rationale: Atropine is a muscarinic antagonist (anticholinergic) that blocks the effects
of acetylcholine at parasympathetic receptors. Blockade of M2 receptors in the heart
causes tachycardia, a desired effect when treating symptomatic bradycardia. Atropine
also causes urinary retention (D) due to decreased detrusor smooth muscle contraction
and increased internal sphincter tone. It causes mydriasis, not miosis (A), and
decreases salivation (B) leading to dry mouth. These anticholinergic effects are
important to monitor .
, Page 4 of 77
22. Which of the following medications is the antidote for a cholinergic crisis?
A. Atropine
B. Pralidoxime
C. Both A and B
D. Naloxone
Correct Answer: C
Rationale: A cholinergic crisis (e.g., due to organophosphate poisoning) involves
excessive accumulation of acetylcholine at muscarinic and nicotinic receptors.
Atropine is administered to block muscarinic receptors (e.g., to reverse bradycardia,
bronchoconstriction, secretions), while pralidoxime reactivates acetylcholinesterase
that has been inhibited by the organophosphate. Atropine treats muscarinic effects but
does not reverse nicotinic effects like muscle paralysis; pralidoxime is needed to
address the enzyme inactivation. Naloxone (D) is an opioid antagonist and would be
ineffective in a cholinergic crisis .
23. A patient is prescribed a beta-blocker for hypertension. Which of the following
monitoring parameters is most important for the nurse to evaluate?
A. Respiratory rate
B. Serum potassium level
C. Heart rate and blood pressure
D. Liver function tests
Correct Answer: C
Rationale: Beta-blockers reduce heart rate and cardiac contractility by blocking beta-1
receptors in the heart and reduce blood pressure by several mechanisms, including
decreased cardiac output and decreased renin release from the kidneys. Therefore,
heart rate and blood pressure are the most important parameters to monitor. A heart
rate below 60 bpm or symptomatic bradycardia, as well as hypotension (systolic BP < 90
mmHg), may require dose reduction or discontinuation. While beta-blockers can affect
the respiratory system (especially nonselective beta-blockers, contraindicated in
asthma due to bronchoconstriction), monitoring respiratory rate is not the primary
parameter for all beta-blocker use .
24. A patient with myasthenia gravis is started on pyridostigmine. Which of the
following best describes the mechanism of action of this medication?
A. Directly stimulates nicotinic receptors at the neuromuscular junction
B. Reversibly inhibits acetylcholinesterase, increasing acetylcholine availability
NSG1 550 PHARMACOLOGY EXAM 2 LATEST VERSION
QUESTIONS AND ANSWERS 2026 EDITION
NSG1 550 PHARMACOLOGY EXAM 2: PRACTICE QUESTIONS WITH RATIONALES
QUESTIONS 1-20: PHARMACOKINETICS AND PHARMACODYNAMICS
1. A patient with renal impairment is receiving a medication that is primarily
eliminated by the kidneys. Which pharmacokinetic parameter would be most
affected, requiring dosage adjustment?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Protein binding
Correct Answer: C
Rationale: For drugs eliminated primarily by the kidneys, renal impairment reduces the
clearance rate, which increases the drug's half-life and prolongs its duration of action.
Volume of distribution (A) is affected by factors such as body composition and tissue
binding rather than renal function. Bioavailability (B) relates to the fraction of an
administered dose that reaches systemic circulation. Protein binding (D) can be altered
by conditions affecting albumin levels, not directly by renal function. In clinical practice,
dosage adjustment (e.g., lower dose, longer interval) is required to prevent drug
accumulation and toxicity when renal clearance is reduced .
2. A drug with high first-pass metabolism is administered. Which route of
administration would best bypass first-pass metabolism?
A. Oral administration
B. Intravenous administration
, Page 2 of 77
C. Sublingual administration
D. Intramuscular administration
Correct Answer: C
Rationale: Sublingual administration allows the drug to be absorbed through the oral
mucosa directly into the systemic circulation, completely bypassing the hepatic portal
system and first-pass metabolism. Intravenous (B) administration also bypasses first-
pass metabolism but requires specialized training for administration. Oral (A)
administration subjects the drug to hepatic first-pass metabolism because it is
absorbed from the GI tract into the portal circulation. Intramuscular (D) administration
avoids first-pass metabolism but involves slower absorption than sublingual .
3. The therapeutic index of a drug is best defined as:
A. The ratio of the median effective dose to the median lethal dose
B. The dose required to produce a therapeutic effect
C. The potency of the drug compared to another drug
D. The maximum effect a drug can produce
Correct Answer: A
Rationale: The therapeutic index (TI) is a safety parameter calculated as the ratio of the
median lethal dose (LD50, dose that kills 50% of subjects) to the median effective dose
(ED50, dose that produces a therapeutic effect in 50% of subjects). A larger therapeutic
index indicates a wider margin of safety, whereas a narrow therapeutic index (e.g.,
warfarin, lithium, phenytoin, digoxin) requires careful monitoring . Potency (C) is defined
by the dose required to achieve a given effect, while efficacy (D) refers to the maximum
effect a drug can produce .
4. A patient is prescribed a drug that is 95% protein-bound and has a narrow
therapeutic index. The nurse should monitor this patient closely for which potential
risk?
A. Enhanced drug effect due to decreased protein binding
B. Reduced drug effect due to increased protein binding
C. Increased drug excretion due to protein saturation
D. No change in drug effect because the drug is highly protein-bound
Correct Answer: A
Rationale: For drugs that are highly protein-bound (e.g., 95%), only the unbound (free)
fraction is pharmacologically active. If a second drug with higher protein-binding affinity
, Page 3 of 77
is co-administered or if protein binding is decreased, the free fraction of the original
drug increases. This can lead to increased drug effect and toxicity even if the total
serum concentration remains within the therapeutic range. This is a critical
consideration for drugs with a narrow therapeutic index, such as phenytoin, warfarin,
and digoxin. The nurse should monitor for signs of toxicity in such situations .
5. A drug that acts as a full agonist at a receptor will produce:
A. No effect regardless of receptor occupancy
B. A maximal effect at 100% receptor occupancy
C. A maximal effect at less than 100% receptor occupancy
D. An effect that is less than that of a partial agonist
Correct Answer: C
Rationale: A full agonist is capable of producing a maximal tissue response. In many
receptor systems, it is not necessary for the agonist to occupy 100% of the receptors to
produce a maximal effect because of the phenomenon of receptor spareness. The
presence of spare receptors means that a maximal response can be achieved when
only a fraction of the receptors are occupied. Partial agonists (D) produce a submaximal
effect even at 100% receptor occupancy .
QUESTIONS 21-40: AUTONOMIC PHARMACOLOGY
21. A patient receiving atropine for bradycardia should be monitored for which of
the following adverse effects?
A. Miosis
B. Increased salivation
C. Tachycardia
D. Urinary retention
Correct Answer: C and D
Rationale: Atropine is a muscarinic antagonist (anticholinergic) that blocks the effects
of acetylcholine at parasympathetic receptors. Blockade of M2 receptors in the heart
causes tachycardia, a desired effect when treating symptomatic bradycardia. Atropine
also causes urinary retention (D) due to decreased detrusor smooth muscle contraction
and increased internal sphincter tone. It causes mydriasis, not miosis (A), and
decreases salivation (B) leading to dry mouth. These anticholinergic effects are
important to monitor .
, Page 4 of 77
22. Which of the following medications is the antidote for a cholinergic crisis?
A. Atropine
B. Pralidoxime
C. Both A and B
D. Naloxone
Correct Answer: C
Rationale: A cholinergic crisis (e.g., due to organophosphate poisoning) involves
excessive accumulation of acetylcholine at muscarinic and nicotinic receptors.
Atropine is administered to block muscarinic receptors (e.g., to reverse bradycardia,
bronchoconstriction, secretions), while pralidoxime reactivates acetylcholinesterase
that has been inhibited by the organophosphate. Atropine treats muscarinic effects but
does not reverse nicotinic effects like muscle paralysis; pralidoxime is needed to
address the enzyme inactivation. Naloxone (D) is an opioid antagonist and would be
ineffective in a cholinergic crisis .
23. A patient is prescribed a beta-blocker for hypertension. Which of the following
monitoring parameters is most important for the nurse to evaluate?
A. Respiratory rate
B. Serum potassium level
C. Heart rate and blood pressure
D. Liver function tests
Correct Answer: C
Rationale: Beta-blockers reduce heart rate and cardiac contractility by blocking beta-1
receptors in the heart and reduce blood pressure by several mechanisms, including
decreased cardiac output and decreased renin release from the kidneys. Therefore,
heart rate and blood pressure are the most important parameters to monitor. A heart
rate below 60 bpm or symptomatic bradycardia, as well as hypotension (systolic BP < 90
mmHg), may require dose reduction or discontinuation. While beta-blockers can affect
the respiratory system (especially nonselective beta-blockers, contraindicated in
asthma due to bronchoconstriction), monitoring respiratory rate is not the primary
parameter for all beta-blocker use .
24. A patient with myasthenia gravis is started on pyridostigmine. Which of the
following best describes the mechanism of action of this medication?
A. Directly stimulates nicotinic receptors at the neuromuscular junction
B. Reversibly inhibits acetylcholinesterase, increasing acetylcholine availability
